1. Circulating cell-derived microparticles as biomarkers in cardiovascular disease
- Author
-
Christina Christersson, Jenny Alfredsson, Agneta Siegbahn, and Åsa Thulin
- Subjects
0301 basic medicine ,Oncology ,medicine.medical_specialty ,Clinical Biochemistry ,Disease ,030204 cardiovascular system & hematology ,03 medical and health sciences ,0302 clinical medicine ,Antigens, CD ,Cell-Derived Microparticles ,Risk Factors ,Internal medicine ,Atrial Fibrillation ,Drug Discovery ,medicine ,Humans ,In patient ,Prospective cohort study ,Heart Failure ,business.industry ,Biochemistry (medical) ,Atherosclerosis ,Prognosis ,030104 developmental biology ,Cardiovascular Diseases ,Risk stratification ,Cardiology ,Shear Strength ,business ,Clinical evaluation ,Circulating Cell-Derived Microparticles ,Biomarkers - Abstract
Cardiovascular diseases (CVDs) are a common cause of death, and a search for biomarkers for risk stratification is warranted. Elevated levels of cell-derived microparticles (MPs) are found in patients with CVD and in groups with risk factors for CVD. Subpopulations of MPs are promising biomarkers for improving risk prediction, as well as monitoring treatment. However, the field has been hampered by technical difficulties, and the ongoing development of sensitive standardized techniques is crucial for implementing MP analyses in the clinic. Large prospective studies are required to establish which MPs are of prognostic value in different patient groups. In this review, we discuss methodological challenges and progress in the field, as well as MP populations that are of interest for further clinical evaluation.
- Published
- 2016
- Full Text
- View/download PDF